Влияние длительного приема антиагрегантных препаратов на воспалительный ответ и эндотелиальную функцию у больных ИБС после стентирования коронарный артерий
Диссертация
Механизм воздействия клопидогреля, как одного из основных антиагрегантных препаратов, на эндотелий и его функцию остается крайне дискутабельным. Так, например, одни исследователи утверждают, что длительный прием Плавикса приводит к уменьшению степени гиперплазии интимы, тем самым существенно снижая показатели общей летальности и заболеваемости после сосудистого вмешательства. Другие опровергают… Читать ещё >
Содержание
- СПИСОК УСЛОВНЫХ СОКРАЩЕНИЙ
- СПРАВОЧНАЯ ИНФОРМАЦИЯ
- ВВЕДЕНИЕ
- ГЛАВА 1. Обзор литературы
- ГЛАВА 2. Материал и методы исследования
- 2. 1. Материал исследования
- 2. 2. Методы исследования
- ГЛАВА 3. Результаты собственных исследований
Список литературы
- Аверков О.В. Алгоритм применения антитромбоцитарных средств при острых коронарных синдромах // Фарматека. -2007. -№ 5. -С. 66−74.
- Аверков О.В. Клопидогрель: новые стандарты антитромбоцитарной терапии при внутрикоронарных вмешательствах и возможные перспективы использования // Фарматека. -2003. -№ 3. -С. 36−41.
- Аверков О.В., Атарщикова М. В. Антитромботические средства и чрескожные коронарные вмешательства: спорные вопросы применения клопидогреля// Фарматека. -2004. -№ 14. -С. 32−39.
- Апекян Б.Г., Подзолков В. П., Бузиашвили Ю. И. и др. Эндоваскулярная хирургия заболеваний сердца и сосудов в XXI веке // Вестник РАМН. -2003.-№ 12.-С. 6−15.
- Баркаган З.С., Костюченко Г. И. Метаболически-воспалительная концепция атеротромбоза и новые подходы к терапии больных // Бюлл. СО РАМН. -2006. -№ 2. -С. 132−138.
- Бокерия Л.А., Алекян Б. Г., Аракелян B.C. и др. Возможности эндоваскулярной хирургии в лечении больных ИБС в сочетании с патологией внутренней сонной артерии // Бюлл. НЦ ССХ им. А.Н.
- Бакулева РАМН (материалы XII Всероссийского съезда сердечнососудистых хирургов). -2006. -№ 5. -С. 169.
- Бокерия Л.А., Алекян Б. Г., Голухова Е. З. и др. Применение стентов с лекарственным антипролиферативным покрытием в лечении больных ишемической болезнью сердца // Креативная кардиология. -2007. -№ 12. -С. 183−200.
- Бокерия Л.А., Бузиашвили Ю. И., Работников B.C. и др. Острый коронарный синдром. Возможности диагностики и лечения. -М.: НЦССХ им. А. Н. Бакулева РАМН, 2004. -286 с.
- Бузиашвили Ю.И., Алекян Б. Г., Асымбекова Э. У. и др. Оценка результатов коронарной ангиопластики и стентирования у больных ИБС с множественным поражением артерий // Кардиоваскулярная терапия и профилактика (Приложение). -2005. -№ 4. -С. 51−52.
- Бузиашвили Ю.И., Асымбекова Э. У., Кипиани Р. В. и др. Прогрессирование атеросклероза после коронарной ангиопластики и стентирования у больных ИБС с множественным поражением артерий // Бюлл. НЦ ССХ им. А. Н. Бакулева РАМН. -2005. -№ 2. -С. 50−55.
- Гукасян Л.В. Эндотелиальная дисфункция у больных ИБС кардиохирургического профиля. Диагностика и методы коррекции: Дис.. канд. мед. наук. -Москва, 2004. -84 с.
- Иващенко A.A. Дифференцированный подход к антитромботической терапии у больных мультифокальным атеросклерозом на госпитальном этапе хирургического лечения ИБС: Дис.. канд. мед. наук. -Москва, 2001.-133 с.
- Интервенционные методы лечения ишемической болезни сердца / под ред. Бокерия Л. А., Алекяна Б. Г., Коломбо А., Бузиашвили Ю. И. -М.: НЦ ССХ им. А. Н. Бакулева РАМН, 2002. -417 с.
- Климович Л.Г. Маркеры активации гемостаза при противотромботической терапии у больных ИБС: Дис.. докт. биол. наук. -Москва, 2000. -220 с.
- Комаров А.Л., Панченко Е. П. Роль воспаления в развитии атеротромбоза: «противовоспалительные» эффекты клопидогрела // Фарматека. -2007. -№ 8−9. -С. 23−29.
- Комаров А.Л., Панченко Е. П., Значение антитромботической терапии для профилактики осложнений атеросклероза // РМЖ. -2003. -№ 19. -С. 1102−1107.
- Коркушко О.В., Лишневская В. Ю. дифференцированный подход к назначению антиагрегантов у больных ИБС старше 60 лет. -2001 (ht1p://socion.net.ua/medJom-nal/articles/cardiology/korkushko.htm).
- Королева О.С., Затейщиков Д. А. Биомаркеры в кардиологии: регистрация внутрисосудистого воспаления // Фарматека. -2007. -№ 8−9. -С. 30−36.
- Латфуллин И.А., Подольская A.A. Антитромботическая терапия ишемической болезни сердца: от быстродействующих антиагрегантов к статинам и оксиду азота. Реально ли? // РФК. -2006. -№ 3. -С. 37−45.
- Панченко Е.П. Концепция атеротромбоза основа патогенеза сердечнососудистых заболеваний. Основные направления антитромботической терапии // РМЖ. -2005. -№ 7. -С. 433−440.
- Семенов А.В. Продукция растворимого Р-селектина тромбоцитами и эндотелиальными клетками: Дис.. канд. биол. наук. -Москва, 2001.
- Семенов А.В., Романов Ю. А., Локтионова С. А. и др. Продукция растворимого Р-селектина тромбоцитами и эндотелиальными клетками // //Биохимия. -1999. -№ 11. -С. 1570.
- Шахнович P.M., Басинкевич А. Б. Маркеры воспаления и ОКС // Кардиология СНГ. -2005. -т. 3. -С. 58−64.
- Adkins J., Castresana M., Wang Z. et al. Rapamycin inhibits release of tumor necrosis factor-alpha from human vascular smooth muscle cells // Am. Surg. -2004. -vol. 70, № 5. -P. 384−387.
- Aggarwal A., Blum A., Sclmeider D. et al. Soluble CD40 ligand is an early initiator of inflammation after coronary intervention // Coron. Artery Dis. -2004. -vol. 15, № 8. -P. 471−475.
- Akbulut M., Ozbay Y., Karaca I. et al. The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention // Coron. Artery Dis. -2004. -vol. 15, № 6. -P. 347−352.
- Albers G., Amarenco P., Easton J. et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy // Chest. -2004. -vol. 126 (Suppl. 3).-P. 483S-512S.
- Altman R. Antithrombotic prevention in vascular disease. Bases for a new strategy in antithrombotic therapy // Thromb. J. -2007. -vol. 5, № 11.
- Ambrose J., Weinrauch M. Thrombosis in ischemic heart disease // Arch. Intern. Med. -1996. -vol. 156, № 13. -P. 1382−1394.
- Angiolillo D., Fernandez-Ortiz A., Bernardo E. et al. Clopidogrel withdrawal is associated with proinflammatory and protlirombotic effects in patients with diabetes and coronary artery disease // Diabetes. -2006. -vol. 55, № 3. -P. 780−784.
- Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // BMJ. -2002. -vol. 324, № 7329. -P. 71−86.
- Armstead V., Minchenko A., Schuhl R. et al. Regulation of P-selectin expression in human endothelial cells by nitric oxide // Am. J. Physiol. -1997. -vol. 273, № 2 (Pt 2). -P. H740-H746.
- Arora R., Platko W., Bhadwar K., Simpfendorfer C. Role of intracoronary thrombus in acute complications during percutaneous transluminal coronary angioplasty // Cathet. Cardiovasc. Diagn. -1989. -vol. 16, № 4. -P. 226−229.
- Ayral Y., Rauch U., Goldin-Lang P. et al. Prolonged application of Clopidogrel reduces inflammation after percutaneous coronary intervention in the porcine model // Cardiovasc. Revasc. Med. -2007. -vol. 8, № 3. -P. 183 188.
- Azar R., Kassab R., Zoghbi A. et al. Effects of Clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease // Am. Heart J. -2006. -vol. 151, № 2. -P. 521. el-521.e4.
- Badimon J., Zaman A., Helft G. et al. Acute coronary syndromes: pathophysiology and preventive priorities // Thromb. Haemost. -1999. -vol. 82, № 2. -P. 997−1004.
- Balaguer-Malfagon J., Pomar-Domingo F., Vilar-Herrero J. et al. Stent thrombosis in the modern era: incidence, outcome and predictive factors // Rev. Esp. Cardiol. -2006. -vol. 59, № 8. -P. 842−845.
- Ballew K. Clopidogrel plus aspirin did not differ from aspirin alone for reducing M3, stroke, and CV death in high risk atherothrombosis // Evid. Based Med. -2006. -vol. 11, № 5. -P. 143.
- Barilli A., Visigalli R., Sala R. et al. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function // Cardiovasc. Res. -2008. -vol. 78, № 3. -P. 563−571.
- Bar-Shavit R., Eldor A., Vlodavski I. Binding of thrombin to subendothelial extracellular matrix: protection and expression of functional properties // J. Clin. Invest. -1989. -vol. 84, № 4. -P. 1096−1104.
- Benezet-Mazuecos J., Ibanez B., Badimon J. Dual antiplatelet therapy and drug eluting stents: a marriage of convenience // Thromb J. -2007. -vol. 5, № l.-P. 15−18.
- Berger P., Bell M., Rihal C. et al. Clopidogrel versus ticlopidine after intracoronary stent placement // J. Am. Coll. Cardiol. -1999. -vol. 34, № 7. -P. 1891−1894.
- Bhatt D., Fox K., Hacke W. et al.- CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events // N. Engl. J. Med. -2006. -vol. 354, № 16. -P. 1706−1717.
- Bledsoe S., Brown A., Davis J. et al. Effect of Clopidogrel on platelet aggregation and intimal hyperplasia following carotid endarterectomy in the rat // Vascular. -2005. -vol. 13, № 1. -P. 43−49.
- Block P., Baughman K., Pasternak R., Fallon J. Transluminal angioplasty: Transluminal angioplasty: correlation of morphologic and angiographic findings in an experimental model // Circulation. -1980. -vol. 61, № 4. -P. 778−785.
- Block P., Meyler R., Stertzer S., Fallon J. Morphology after transluminal angioplasty in human beings // N. Eng. J. Med. -1981. -vol. 305, № 7. -P. 382−385.
- Blum A., Schneider D., Sobel B., Dauerman H. Endothelial dysfunction and inflammation after percutaneous coronary intervention // Am. J. Cardiol. -2004. -vol. 94, № 11. -P. 1420−1423.
- Boos C., Balakrishnan B., Jessani S. Effects of percutaneous coronary intervention on peripheral venous blood circulating endothelial cells and plasma indices of endothelial damage/dysfunction // Chest. -2007. -vol. 132, № 6. -P. 1920−1926.
- Boston Scientific. Resources for healthcare professionals. Data on the drug-eluting stent safety debate (http://www.taxus-stent.com / accessed Feb 2007).
- Brasselet C., Garnotel R., Perotin S. et al. Percutaneous coronary intervention-induced variations in systemic parameters of inflammation: relationship with the mode of stenting // Clin. Chem. Lab. Med. -2007. -vol. 45, № 4. -P. 526 530.
- Brilakis E., Banerjee S., Berger P. The risk of drug-eluting stent thrombosis with noncardiac surgery // Curr. Cardiol. Rep. -2007. -vol. 9, № 5. -P. 406 411.
- Caixeta A., Brito F.-Jr., Costa M. et al. Enhanced inflammatory response to coronary stenting marks the development of clinically relevant restenosis // Catheter. Cardiovasc. Interv. -2007. -vol. 69, № 4. -P. 500−507.
- Callow A. Endothelial dysfunction in atherosclerosis // Vascul. Pharmacol. -2002. -vol. 38, № 5. -P. 257−258.
- Calver A., Blows L., Harmer S. et al. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents // Am. Heart J. -2000. -vol. 140, № 3. -P. 483 491.
- CAPRIE steering Committee: A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) // Lancet. -1996. -vol. 348, № 9038. -P. 1329−1339.
- Caramori P., Lima V., Seidelin P. et al. Long-term endothelial dysfunction after coronary artery stenting // J. Am. Coll. Cardiol. -1999. -vol. 34, № 6,-P. 1675−1679.
- Celermajer D., Sorensen K., Gooch V. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis // Lancet. -1992.-vol. 340, № 8828.-P. 1111−1115.
- Celik T., Iyisoy A., Kursaklioglu H., Celik M. The forgotten player of in-stent restenosis: endothelial dysfunction // Int. J. Cardiol. -2008. -vol. 126, № 3. -p. 443−444.
- Chapman M. From pathophysiology to targeted therapy for atherothrombosis: A role for the combination of statin and aspirin in secondary prevention // Pharmacol. Ther. -2007. -Vol. 113, № 1. -P. 184−196.
- Chen M., John J., Heart D. et al. Bare metal stent restenosis is not a benign clinical entity// Am. Heart J. -2006. -vol. 151, № 6. -P. 1260−1264.
- Chesebro J., Lam J., Badimon L., Fuster V. Restenosis after arterial angioplasty: a hemorrheologic response to injury // Am. J. Cardiol. -1987. -vol. 60, № 3. -P. 10B-16B.
- Chesebro J., Webster M., Reeder G. Coronary angioplasty: antiplatelet therapy reduces acute complications but not restenosis abstract. // Circulation. -1989. -vol. 80 (suppl. 2). -P. 11−64.
- Chew D., Bhatt D., Robbins M. et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein//Am. J. Cardiol. -2001. -vol. 88, № 6. -P. 672−674.
- Cines D., Pollak E., Buck C. et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders // Blood. -1998. -vol. 91, № 10. -P. 3527−3561.
- Collet J., Montalescot G., Blanchet B. et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes // Circulation. -2004. -vol. 110, № 16. -P. 2361−2367.
- Conde I., Kleiman N. Arterial thrombosis for the interventional cardiologist: from adhesion molecules and coagulation factors to clinical therapeutics // Catheter. Cardiovasc. Interv. -2003. -vol. 60, № 2. -P. 236−246.
- Cortelekoglu T., Bozkurt A., Ustundag N. et al. The effects of clopidogrel and calcium dobesilate on intimal hyperplasia following vascular injury // Acta Chir. Belg. -2006. -vol. 106, № 2. -P. 206−210.
- Cutlip D., Baim D., Ho K. et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials // Circulation. -2001. -vol. 103, № 15. -P. 1967−1971.
- Cutlip D., Leon M., Ho K. et al. Acute and nine-month clinical outcomes after «suboptimal» coronary stenting: results from the STent Anti-thrombotic Regimen Study (STARS) registry // J. Am. Coll. Cardiol. -1999. -vol. 34, № 3.-P. 698−706.
- Diener H., Ringleb P., Savi P. Clopidogrel for secondary prevention of stroke // Expert Opin. Pharmacother. -2005. -Vol. 6, № 5. -P. 755−764.
- Eisenstein E., Anstrom K., Kong D. et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation // JAMA. -2007. -vol. 297, № 2. -P. 159−168.
- Ellis S., Roubin G., King S.-3rd et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty // Circulation. -1998. -vol. 77, № 2. -P. 372−379.
- Falk E., Shah P., Fuster V. Coronary plaque disruption // Circulation. -1995. -vol. 92, № 3.-P. 657−671.
- Farb A., Heller P., Shroff S. et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent // Circulation. -2001. -vol. 104, № 4. -p. 473−479.
- Farb A., Weber D., Kolodgie F. et al. Morphological predictors of restenosis after coronary stenting in humans // Circulation. -2002. -vol. 105, № 25. -P. 2974−2980.
- Fattori R., Piva T. Drug-eluting stents in vascular intervention. Lancet. -2003. -vol. 361, № 9353. -P. 247−249.
- Faxon D., Weber V., Haudenschild C. et al. Acute effects of transluminal angioplasty in three experimental models of atherosclerosis // Arteriosclerosis. -1982. -vol. 2, № 2. -P. 125−133.
- Ferguson J. The role of oral antiplatelet agents in atherothrombotic disease // Am. J. Cardiovasc. Drugs. -2006. -vol. 6, № 3. -P. 149−157.
- Fernandez-Ortiz A., Badimon J., Falk E. et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture // J. Am. Coll. Cardiol. -1994. -vol. 23, № 7. -P. 1562−1569.
- Fitzgerald D., Catella F., Roy L., Fitzgerald G. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction // Circulation. -1988. -vol. 77, № 1. -P. 142−150.
- Freson K., Thys C., Wittevrongel C., Van Geet C. Mechanisms of action and targets for actual and future antiplatelet drugs // Mini Rev. Med. Chem. -2006. -vol. 6, № 6. -P. 719−726.
- Fuke S., Maekawa K., Kawamoto K. et al. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation // Circ. J. -2007. -vol. 71, № 2. -P. 220−225.
- Fukuda D., Sata M., Tanaka K., Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells // Circulation. -2005. -vol. Ill, № 7. -P. 926−931.
- Fukuda D., Shimada K., Tanaka A. et al. Circulating monocytes and in-stent neointima after coronary stent implantation // J. Am. Coll. Cardiol. -2004. -vol. 43, № l.-P. 18−23.
- Fuster V. Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology // Circulation. -1994. -vol. 90, № 4. -P. 2126−2146.
- Fuster V., Badimon J., Badimon L. Clinical-pathological correlations of coronary disease progression and regression // Circulation. -1992. -vol. 86, № 6 (suppl.).-P. mi-III 11.
- Fuster V., Badimon J., Chesebro J. Atherothrombosis: mechanisms and clinical therapeutic approaches // Vase Med. -1998. -vol. 3, № 3. -P. 231 239.
- Fuster V., Fayad Z., Badimon J. Acute coronary syndromes: biology // Lancet. -1999. -vol. 353 (supple 2). -P. SII5-SII9.
- Fuster V., Moreno P., Fayad Z. et al. Atherothrombosis and high-risk plaque: part I: evolving concepts // J. Am. Coll. Cardiol. -2005. -Vol. 46, № 6. -P. 937−954.
- Garg R., Uretsky B., Lev E. et al. Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention // Catheter. Cardiovasc. Interv. -2007. -vol. 70, № 3. -P. 388−406.
- Gaspardone A., Crea F., Versaci F. et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina //Am. J. Cardiol. -1998. -vol. 82, № 4. -P. 515−518.
- Gaspardone A., Versaci F. Coronary stenting and inflammation // Am. J. Cardiol. -2005. -vol. 96, № 12A. -P. 65L-70L.
- Gaspardone A., Versaci F., Tomai F. et al. C-Reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents //Am. J. Cardiol. -2006. -vol. 97, № 9. -P. 1311−1316.
- Gawaz M., Langer H., May A. Platelets in inflammation and atherogenesis // J. Clin. Invest. -2005. -vol. 115, № 12. -P. 3378−3384.
- Gawaz M., Neumann F., Ott I. et al. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy // Circulation. -1996. -vol. 94, № 3. -P. 279−285.
- Gogo P.-Jr., Schneider D., Watkins M. et al. Systemic inflammation after drug-eluting stent placement // J. Thromb. Thrombolysis. -2005. -vol. 19, № 2. -P. 87−92.
- Gotsch U., Jager U., Dominis M. et al. Expression of P-selectin on endothelial cells is upregulated by LPS and TNF-alpha in vivo // Cell Adhes. Commun. -1994.-vol. 2, № 1. -P. 7−14.
- Granger D., Vowinkel T., Petnehazy T. Modulation of the Inflammatory Response in Cardiovascular Disease // Hypertension. -2004. -vol. 43, № 5. -P. 924−931.
- Grewe P., Deneke T., Machraoui A. et al. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen // J. Am. Coll. Cardiol. -2000. -vol. 35, № 1. -P. 157−163.
- Gurbel P., Samara W., Bliden K. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis // Platelets. -2004. -vol. 15, № 2. -P. 95−99.
- Hadjadj S., Cloutier I., Geoffroy P., Tanguay J. Stent implantation in coronary porcine arteries is associated with early activation of TNFalpha and TNFalpha receptor II expression // Atherosclerosis. -2007. -vol. 192, № 1. -P. 25−32.
- Harper R. Drug-eluting coronary stents a note of caution // Med. J. Aust. -2007. -vol. 186, № 5. -P. 253−255.
- Hayashi S., Watanabe N., Nakazawa K. et al. Roles of P-selectin in inflammation, neointimal formation, and vascular remodeling in ballooninjured rat carotid arteries // Circulation. -2000. -vol. 102, № 14. -P. 17 101 717.
- Helgason C., Bolin K., Hoff J. et al. Development of aspirin resistance in persons with previous ischemic stroke // Circulation. -1994. -vol. 25, № 12. -P. 2331−2336.
- Helgason C., Tortorice K., Winkler S. et al. Aspirin response and failure in cerebral infarction // Stroke. -1993. -vol. 24, № 3. -P. 345−350.
- Henn V., Slupsky J., Grafe M. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells // Nature. -1998. -vol. 391, № 6667. -P. 591−594.
- Henn V., Steinbach S., Buchner K. et al. The inflammatory action of CD40 ligand (CD 154) expressed on activated human platelets is temporally limited by coexpressed CD40 // Blood. -2001. -vol. 98, № 4. -P. 1047−1054.
- Herbert J., Frehel D., Vallee E. et al. Clopidogrel, a novel antiplatelet and antithrombotic agent// Cardiovasc. Drugs Rev. -1993. -vol. 11. -P. 180−198.
- Hermann A., Rauch B., Braun M. et al. Platelet CD40 ligand (CD40L) subcellular localization, regulation of expression, and inhibition by Clopidogrel // Platelets. -2001. -vol. 12, № 2. -P. 74−82.
- Hill R., Dundar Y., Bakhai A. et al. Drug-eluting stents: an early systematic review to inform policy // Eur. Heart J. -2004. -vol. 25, № 11. -P. 902−919.
- Hogg P., Jackson C. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy // Proc. Natl. Acad. Sei. USA. -1989. -vol. 86, № 10. -P. 3619−3623.
- Hojo Y., Ikeda U., Katsuki T. et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis // Heart. -2000. -vol. 84, № 1. -P. 83−87.
- Holt J., Niewiarowski S. Biochemistry of alpha granule proteins // Semin. Haematol. -1985. -vol. 22, № 2. -P. 151−163.
- Iakovou I., Schmidt T., Bonizzoni E. et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drag-eluting stents // JAMA. -2005. -vol. 293, № 17. -P. 2126−2130.
- Inoue T., Uchida T., Yaguchi I. et al. Stent-induced expression and activation of the leukocyte integrin mac-1 is associated with neointimal thickening and restenosis // Circulation. -2003. -vol. 107, № 13. -P. 1757−1763.
- Inwald D., McDowall A., Peters M. et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation // Circ. Res. -2003. -vol. 92, № 9. -P. 1041−1048.
- Jabs W., Theissing E., Nitschke M. et al. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue // Circulation. -2003. -vol. 108, № 3. -P. 1428−1431.
- Jeanmart H., Malo O., Carrier M. et al. Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function // J. Heart Lung Transplant. -2002. -vol. 21- № 9. -P. 990−998.
- Jenkins N., Prendergast B., Thomas M. Drug eluting coronary stents. BMJ. -2002. -vol. 325, № 7376. -P. 1315−1316.
- Jeong M., Owen W., Staab M. et al. Porcine model of stent thrombosis: platelets are the primary component of acute stent closure // Cathet. Cardiovasc. Diagn. -1996. -vol. 38, № 1. -P. 38−43.
- Joner M., Finn A., Farb A. et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk // J. Am. Coll. Cardiol. -2006. -vol. 48, № l.-P. 193−202.
- Judkins M. Selective coronary arteriography. I. A percutaneous transfemoral technic // Radiology. -1967. -vol. 89, № 5. -P. 815−824.
- Kameda H., Morita I., Handa M. et al. Re-expression of functional p-selectin molecules on the endothelial cell surface by repeated stimulation with thrombin // Br. J. Haematol. -1997. -vol. 97, № 2. -P. 348−355.
- Kastrati A., Koch W., Berger P. et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting // J. Am. Coll. Cardiol. -2000. -vol. 36, № 7. -P. 2168−2173.
- Kefer J., Galanti L., Desmet S. et al. Time course of release of inflammatory markers after coronary stenting: comparison between bare metal stent and sirolimus-eluting stent // Coron. Artery Dis. -2005. -vol. 16, № 8. -P. 505 509.
- Khew-Goodall Y., Butcher C., Litwin M. et al. Chronic expression of P-selectin on endothelial cells stimulated by the T-cell cytokine, interleukin-3 // Blood. -1996. -vol. 87, № 4. -P. 1432−1438.
- Kikano G., Brown M. Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician // Mayo Clin. Proc. -2007. -vol. 82, № 5. -P. 583−593.
- Klugherz B., Llanos G., Lieuallen W. et al. Twenty-eight-day efficacy and pharmacokinetics of the sirolimus-eluting stent // Coron. Artery Dis. -2002. -vol. 13, № 3.-P. 183−188.
- Kohchi K., Takebayashi S., Block P. et al. Arterial changes after percutaneous transluminal coronary angioplasty: results at autopsy // J. Am. Coll. Cardiol. -1987. -vol. 10, № 3. -P. 592−599.
- Kornowski R., Hong M., Tio F. et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia // J. Am. Coll. Cardiol. -1998. -vol. 31, № 1. -P. 224−230.
- Kotani J., Awata M., Nanto S. et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings // J. Am. Coll. Cardiol. -2006. -vol. 47, № 10.-P. 2108−2111.
- Kozinski M., Kubica J., Sukiennik A. et al. Periprocedural soluble P- and E-selectin levels fail as predictors of clinical restenosis in patients treated with elective coronary stenting // Int. J. Mol. Med. -2007. -vol. 19, № 1. P. 187 195.
- Lam J., Chesebro J., Steele P. et al. Antithrombotic therapy for deep arterial injury by angioplasty: efficacy of common platelet inhibition compared with thrombin inhibition in pigs // Circulation. -1991. -vol. 84, № 2. -P. 814−820.
- Leon M., Baim D., Popma J. et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators // N. Engl. J. Med. -1998. -vol. 339, № 23. -P. 1665−1671.
- Li J., Qin X., Yang X. et al. Randomized comparison of early inflammatory response after sirolimus-eluting stent vs bare metal stent implantation in native coronary lesions // Clin. Chim. Acta. -2008. -vol. 396, № 1−2. -P. 3842.
- Liao J., Laufs U. Pleiotropic effects of statins // Annu. Rev. Pharmacol. Toxicol. -2005. -vol. 45. -P. 89−118.
- Libby P., Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets // Nat. Med. -2002. -Vol. 8, № 11. -P. 12 571 262.
- Lyon R., Zarins C., Lu C. et al. Vessel, plaque, and lumen morphology after transluminal balloon angioplasty. Quantitative study in distended human arteries //Arteriosclerosis. -1987. -vol. 7, № 3. -P. 306−314.
- Madjid M., Zarrabi A., Litovsky S. et al. Finding vulnerable atherosclerotic plaques: is it worth the effort? // Arterioscler. Thromb. Vase. Biol. -2004. -Vol. 24, № 10. -P. 1775−1782.
- Mahemuti A., Meneveau N., Seronde M. et al. Early local intracoronary platelet activation after drug-eluting stent placement // Chin. Med. J. (Engl). -2007. -vol. 120, № 22. -P. 1986−1991.
- Malek A., Alper S., Izumo S. Hemodynamic shear stress and its role in atherosclerosis // JAMA. -1999. -vol. 282, № 21. P. 2035−2042.
- Massberg S., Gruner S., Konrad I. et al. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice // Blood. -2004. -vol. 103, № l. -p. 136−142.
- Massel D., Hudoba M., Weitz J. Clot-bound thrombin is protected from heparin inhibition — a potential mechanism for rethrombosis after lytic therapy abstract. // Circulation. -1989. -vol. 80 (suppl. 2). -P. 11−420.
- Matzdorff A., Kemkes-Matthes B., Voss R. Comparison of beta thromboglobulin, flow cytometry and platelet aggregometry to study platelet activation // Haemostasis. -1996. -vol. 26, № 2. -P. 98−106.
- Mctavish D., Faulds D., Goa K. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders // Drugs. -1990. -vol. 40, № 2. -P. 238−259.
- Mishkel G., Aguirre F., Ligon R. et al. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting // J. Am. Coll. Cardiol. -1999. -vol. 34, № 7. -P. 1884−1890.
- Mizia-Stec K. Cytokines and adhesive molecules in detection of endothelial dysfunction//Pharmacol Rep. -2006. -vol. 58 (Suppl.). -P. 21−32.
- Mizia-Stec K., Gsior Z., Zahorska-Markiewicz B. et al. Inflammatory markers in a 2-year follow-up of coronary artery disease // Heart Vessels. -2006. -vol. 21, № 5. -P. 302−308.
- Mizuno K., Miyamoto A., Shibuya T. et al. Changes of angioscopic macromorphology following coronary angioplasty abstract. // Circulation. -1988. -vol. 78 (suppl. 2). -P. 11−289.
- Morange P., Simon C., Alessi M. et al. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study// Circulation. -2004. -vol. 109, № 11. -P. 1343−1348.
- Moreno P. Atherothrombosis: the global approach for a global disease. Pathophysiology of atherothrombosis. Highlights monograph from an International expert meeting on atherombosis. — Milan, 1998.
- Moreno R., Fernandez C., Hernandez R. et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies // J. Am. Coll. Cardiol. -2005. -vol. 45, № 6. -P. 954−959.
- Morice M., Serruys P., Barragan P. et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial // J. Am. Coll. Cardiol. -2007. -vol. 50, № 14. -P. 1299−1304.
- Moussa I., Oetgen M., Roubin G. et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation // Circulation. -1999. -vol. 99, № 18. -P. 23 642 366.
- Mruk J., Chesebro J., Webster M. Platelet aggregation and interaction with the coagulation system: implications for antithrombotic therapy in arterial thrombosis // Coron. Artery Dis. -1990. -vol. 1. -P. 149−155.
- Mueller C., Roskamm H., Neumann F. et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents // J. Am. Coll. Cardiol. -2003. -vol. 41, № 6. -P. 969 973.
- Munger M., Hawkins D. Atherothrombosis: epidemiology, pathophysiology, and prevention // J. Am. Pharm. Assos. -2004. -Vol. 44, № 2 (Suppl. 1). -P. S5-S12.
- Narins C., Hillegass W.-Jr., Nelson C. et al. Relation between activated clotting time during angioplasty and abrupt closure // Circulation. -1996. -vol. 93, № 4.-P. 667−671.
- Neumann F., Gawaz M., Ott I. et al. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting // J. Am. Coll. Cardiol. -1996. -vol. 27, № 1. -P. 15−21.
- Norris J., Barnett H. CHARISMA: The Antiplatelet Saga Continues // Stroke. -2006. -vol. 37, № 9. -P. 2428−2429
- Ozer N., Tangurek B., Firat F. et al. Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention // Heart. Vessels. -2008. -vol. 23, № 2. -P. 75−82.
- Patel S., Celermajer D. Assessment of vascular disease using arterial flow mediated dilatation // Pharmacological reports. -2006. -vol. 58 (suppl.). P. 3−7.
- Patrono C. Aspirin as an antiplatelet drug // N. Eng. J. Med. -1994. -vol. 330, № 18.-P. 1287−1294.
- Pitchford S. Novel uses for anti-platelet agents as anti-inflammatory drugs // Br. J. Pharmacol. -2007. -vol. 152, № 7. -P. 987−1002.
- Platelet glycoprotein Ilb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators // N. Engl. J. Med. -1997. -vol. 336, № 24. -P. 1689−1696.
- Quinn M., Fitzgerald D. Ticlopidine and clopidogrel // Circulation. -1999. -vol. 100, № 15. -P. 1667−1672.
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study // Lancet. -1997. -vol. 349, № 9063. -P. 1429−1435.
- Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II // Lancet. -1997. -vol. 349, № 9063. -P. 1422−1428.
- Rinder C., Student L., Bonan J. et al. Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release // Blood. -1993. -vol. 82, № 2.-P. 505−512.
- Rogers C., Welt F., Karnovsky M. et al. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin // Arterioscler. Thromb. Vase. Biol. -1996. -vol. 16, № 10. -P. 1312−1318.
- Romano M., Avellino R., Petrella A. et al. Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells // Eur. J. Cancer. -2004. -vol. 40, № 18. -P. 2829−2836.
- Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s // Nature. -1993. -vol. 362, № 6423. -P. 801−809.
- Sacristan D., Lopez-Farre A., Zamorano-Leon J. et al. Effects of coronary prestenting platelet inhibition on coronary poststenting inflammation // J. Cardiovasc. Pharmacol. -2008. -vol. 51, № 3. -P. 286−292.
- Saia F., Schaar J., Regar E. et al. Clinical imaging of the vulnerable plaque in the coronary arteries: new intracoronary diagnostic methods // J Cardiovasc. Med. (Hagerstown). -2006. -Vol. 7, № 1. -P. 21−28.
- Saini H., Xu Y., Arneja A. et al. Pharmacological basis of different targets for the treatment of atherosclerosis // J. Cell Mol. Med. -2005. -vol. 9, № 4. -P. 818−839.
- Sanborn T., Faxon D., Haudenschild C. et al. The mechanism of transluminal angioplasty: evidence for formation of aneurysms in experimental atherosclerosis // Circulation. -1983. -Vol. 68, № 5. -P. 1136−1140.
- Santos M., Valles J., Aznar J. et al. Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin // Circulation. -1997. -vol. 95, № 1. -P. 63−68.
- Scheen A., Radermecker R., De Flines J., Ducobu J. Recent treatment perspectives in lipidology // Rev. Med. Liege. -2007. -vol. 62, № 5−6. -P. 324−328.
- Scheuerer B., Ernst M., Durrbaum-Landmann I. et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages // Blood. -2000. -vol. 95, № 4. -P. 11 581 166.
- Schoenbeck U., Libby P. The CD40/CD154 receptor/ligand dyad // Cell Mol. Life Sci. -2001. -vol. 58, № 1. -P. 4−43.
- Schomig A., Neumann F., Kastrati A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents //N. Engl. J. Med. -1997. -vol. 334, № 17. -P. 1084−1089.
- Schwartz L., Bourassa M., Lesperance J. et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty//N. Eng. J. Med. -1988. -vol. 318, № 26. -P. 1714−1719.
- Schwartz R., Holmes D.-Jr., Topol E. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms // J. Am. Coll. Cardiol. -1992. -vol. 20, № 5.-P. 1284−1293.
- Seldinger S. Catheter replacement of the needle in percutaneous arteriography- a new technique // Acta radiol. -1953. -vol. 39, № 5. -P. 368 376.
- Shin D., Kim P., Seung K. et al. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction // Int. Heart J. -2007. -vol. 48, № 5. -P. 553−567.
- Shuchman M. Debating the risks of drug-eluting stents // N. Eng. J. Med. -1992. -vol. 356, № 4. -P. 325−328.
- Sigwart U. Drug-eluting stents are safe and effective: right or wrong? // J. Am. Coll. Cardiol. -1992. -vol. 47, № 7. -P. 1361−1362.
- Solheim S., Pettersen A., Arnesen H., Seljeflot I. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease // Thromb. Haemost. -2006. -vol. 96, № 5. -P. 660−664.
- Stary H., Chandler A., Dinsmore R. et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on
- Arteriosclerosis, American Heart Association // Arterioscler. Thromb. Vase.7
- Biol. -1995. -vol. 15, № 9. -P. 1512−1531.
- Steinhubl S., Badimon J., Bhatt D. et al. Clinical evidence for antiinflammatory effects of antiplatelet therapy in patients with atherothrombotic disease // Vase. Med. -2007. -vol. 12, № 2. -P. 113−122.
- Steinhubl S., Lauer M., Muklierjee D. et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedurerelatednon-Q-wave myocardial infarctions // J. Am. Coll. Cardiol. -1998. -vol. 32, № 5. -P. 1366−1370.
- Stone G., Aronow H. Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy // Mayo Clin. Proc. -2006. -vol. 81, № 5. -P. 641−652.
- Sun J., Maguire D. How to prevent perioperative myocardial injury: the conundrum continues //Am. Heart J. -2007. -vol. 154, № 6. -P. 1021−1028.
- Suzuki T., Kopia G., Hayashi S. et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model // Circulation. -2001.-vol. 104, № 10.-P. 1188−1193.
- Szmitko P., Wang C., Weisel R. et al. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II // Circulation. -2003. -vol. 108, № 17. -P. 2041−2048.
- Szmitko P., Wang C., Weisel R. et al. New markers of inflammation and endothelial cell activation: Part I // Circulation. -2003. -vol. 108, № 18. -P. 1917−1923.
- Taniuchi M., Kurz H., Smith S. et al. Ticlopidine or Plavix Post-Stent (TOPPS): randomization to 2-week treatment abstract. // Circulation. -1999. -vol. 100 (suppl. 1). -P. 1−379.
- Teitel J., Rosenberg R. Protection of factor Xa from neutralization by heparin-antithrombin complex // J. Clin. Invest. -1983. -vol. 71, № 5. -P. 1383−1391.
- Tesfamariam B. Local vascular toxicokinetics of stent-based drug delivery // Toxicol. Lett. -2007. -vol. 168, № 2. -P. 93−102.
- The EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade // Lancet. -1998. -vol. 352, № 9122. -P. 87−92.
- Tomai F., Ghini A., Ferri C. et al. Effects of carbon-coated coronary stents on the markers of inflammation, thrombin generation and platelet and endothelial activation // Ital. Heart J. -2003. -vol. 4, № 1. p. 23−28.
- Toutouzas K., Colombo A., Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions // Eur. Heart J. -2004. -vol. 25, № 19. -P. 1679−1687.
- Uchida Y., Hasegawa K., Kawamura K., Shibuya I. Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplasty // Am. Heart J. -1989. -vol. 117, № 4. -P. 769−776.
- Ueda Y., Hirayama A., Kodama K. Plaque characterization and atherosclerosis evaluation by coronary angioscopy // Herz. -2003. -Vol. 28, № 6. -P. 501−504.
- US Food and Drug Administration. FDA statement on coronary drug-eluting stents. -2006 (September 14). -http://www.fda.gov/cdrh/news/91 406.html (accessed Feb 2007).
- US Food and Drug Administration. Update to FDA statement on coronary drug-eluting stents. -2007 (January 4). -http://www.fda.gov/cdrh/news/10 407.html (accessed Feb 2007).
- Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty // N. Engl. J. Med. -1994. -vol. 330, № 14.-P. 956−961.
- Verma S., Buchanan M., Anderson T. Endothelial function testing as a biomarker of vascular disease // Circulation. -2003. -vol. 108, № 17. -P. 2054−2059.
- Viles-Gonzalez J., Anand S., Valdiviezo C. et al. Update in atherothrombotic disease // Mt. Sinai J. Med. -2004. -vol. 71, № 3. -P. 197−208.
- Virmani R., Guagliumi G., Farb A. et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? // Circulation. -2004. -vol. 109, № 6. -P. 701−705.
- Wallen H., Ladjevardi M. Influence of low- and high-dose aspirin treatment on thrombin generation in whole blood // Thromb. Res. -1998. -vol. 92, № 4. -P. 189−194.
- Waller B., Pinkerton C., Orr C. et al. Restenosis 1 to 24 months after clinically successful coronary balloon angioplasty: a necropsy study of 20 patients // J. Am. Coll. Cardiol. -1991. -vol. 17, № 6 (suppl. B). -P. 58B-70B.
- Walter T., Szabo S., Kazmaier S. et al. Effect of clopidogrel on adhesion molecules, hemostasis, and fibrinolysis in coronary heart disease // J. Cardiovasc. Pharmacol. -2008. -vol. 51, № 6. -P. 616−620.
- Wang K., Zhou Z., Zhou X. et al. Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model // J. Am. Coll. Cardiol. -2001. -vol. 38, № 2. -P. 577−582.
- Weidinger F., McLenachan J., Cybulsky M. et al. Persistent dysfunction of regenerated endothelium after balloon angioplasty of rabbit iliac artery // Circulation. -1990. -vol. 81, № 5. -P. 1667−1679.
- Weitz J., Hudoba M., Massel D. et al. Clot bound thrombin is protected from inhibition by heparin antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors // J. Clin. Invest. -1990. -vol. 86, № 2.-P. 385−391.
- Welt F., Tso C., Edelman E. et al. Leukocyte recruitment and expression of chemokines following different forms of vascular injury // Vase. Med. -2003. -vol. 8,№ l.-P. 1−7.
- Wenaweser P. Drug-eluting stent: long term follow-up // Presented at the European Society of Cardiology Scientific Congress. -2006, September 2−6. -Barcelona, Spain.
- Wenaweser P., Hess O. Stent thrombosis is associated with an impaired response to antiplatelet therapy // J. Am. Coll. Cardiol. -2005. -vol. 46, № 5. -P. CS5- CS6.
- Wexberg P., Jordanova N., Strehblow C. et al. Time course of protlirombotic and proinflammatory substance release after intracoronary stent implantation // Thromb. Haemost. -2008. -vol. 99, № 4. -P. 739−748.
- White C., Chaitman B., Lassar T. et al. Antiplatelet agents are effective in reducing the immediate complications of PTCA: results from the Ticlopidine Multicenter Trial abstract. // Circulation. -1987. -vol. 76 (suppl 4). -P. IV-400.
- White C., Ramee S., Collins T. et al. Coronary angioscopy of abrupt occlusionafter angioplasty // J. Am. Coll. Cardiol. -1995. -vol. 25, № 7. -P. 1681i1684.
- White C., Ramee S., Collins T. et al.: Coronary thrombi increase PTCA risk // Angioscopy as a clinical tool // Circulation. -1996. -vol. 93, № 2. -P. 253 258.
- Wilentz J., Sanborn T., Haudenschild C. et al. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation. -1987. -vol. 75, № 3. -P. 636−642.
- Wilson J., Ferguson J.-3rd Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications // Clin. Cardiol. -1999. -Vol. 22, № 11.-P. 687−698.
- Yasojima K., Schwab C., McGeer E., McGeer P. Generation of C-reactive protein and complement components in atherosclerotic plaque // Am. J. Pathol. -2001. -vol. 158, № 3. -P. 1039−1051.
- Yeh E., Khan B. The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis // J. Thromb. Haemost. -2006. -vol. 4, № 11.-P. 2308−2316.
- Yusuf S. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial. Late Breaking Clinical Trials. In Proceedings of the 50th Annual Scientific Session of the American College of Cardiology. -2001, March 18−21.-Orlando, FL.